Stock Price Movement and Market Context
On 21 Jan 2026, Brooks Laboratories Ltd recorded its lowest price in the past year at Rs.64.25. This new low comes after a prolonged period of decline, with the stock falling for 11 consecutive days before registering a modest gain today. Despite this slight uptick, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.
In comparison, the broader Sensex index has also been under pressure, falling by 0.8% today to 81,525.00 points after a negative opening. The Sensex has declined by 4.94% over the past three weeks, reflecting a challenging environment for equities. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, suggesting some underlying resilience in the broader market.
Brooks Laboratories Ltd outperformed its sector today by 1.23%, yet this relative strength has not been sufficient to offset the stock’s longer-term downtrend.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Long-Term Performance and Valuation Metrics
Over the last year, Brooks Laboratories Ltd has delivered a total return of -59.13%, significantly underperforming the Sensex, which gained 7.49% during the same period. The stock’s 52-week high was Rs.171.70, highlighting the extent of the decline from its peak.
The company’s long-term growth has been modest, with net sales increasing at an annualised rate of 4.36% over the past five years. Return on Equity (ROE) has averaged a low 2.42%, reflecting limited profitability relative to shareholder equity. Additionally, the company’s ability to service debt remains constrained, with an average EBIT to interest ratio of -3.69, indicating earnings before interest and tax have been insufficient to cover interest expenses.
Brooks Laboratories Ltd has also underperformed the BSE500 index over multiple time frames, including the last three years, one year, and three months, underscoring persistent challenges in generating shareholder value.
Recent Financial Highlights
Despite the subdued stock performance, the company has reported some positive financial results in recent quarters. Net sales for the latest six months stood at Rs.48.96 crores, growing by 26.45%. Profit before tax excluding other income (PBT less OI) for the most recent quarter was Rs.7.59 crores, representing a remarkable growth of 2563.2% compared to the previous four-quarter average.
Operating cash flow for the year reached Rs.2.63 crores, the highest recorded in recent periods. The company has declared positive results for four consecutive quarters, with net sales growth of 4.06% reported in September 2025.
Valuation metrics indicate a Price to Book Value of 1.7 and an improved ROE of 12.1 in the latest period, suggesting a more attractive valuation relative to historical averages and peer comparisons. The PEG ratio stands at 0.1, reflecting the relationship between price, earnings growth, and valuation.
Holding Brooks Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Mojo Score and Market Capitalisation Assessment
Brooks Laboratories Ltd currently holds a Mojo Score of 37.0, with a Mojo Grade of Sell as of 22 Dec 2025, an improvement from its previous Strong Sell rating. The market capitalisation grade is rated at 4, reflecting the company’s mid-cap status within the Pharmaceuticals & Biotechnology sector.
The majority shareholding remains with promoters, maintaining a stable ownership structure.
Summary of Key Metrics
The stock’s recent decline to Rs.64.25 represents a significant correction from its 52-week high of Rs.171.70. While the company has demonstrated some positive financial trends in recent quarters, including improved profitability and sales growth, the overall long-term performance and valuation metrics continue to reflect challenges in sustaining growth and returns.
Brooks Laboratories Ltd’s stock remains below all major moving averages, signalling continued caution in price momentum. The broader market environment, with the Sensex experiencing a three-week consecutive fall, adds to the subdued sentiment surrounding the stock.
Investors and market participants will note the contrast between the company’s recent operational improvements and the persistent downward pressure on its share price over the past year.
Unlock special upgrade rates for a limited period. Start Saving Now →
